WO2012060594A3 - Composition anti-inflammatoire contenant un composé thiourée et un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif - Google Patents

Composition anti-inflammatoire contenant un composé thiourée et un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif Download PDF

Info

Publication number
WO2012060594A3
WO2012060594A3 PCT/KR2011/008205 KR2011008205W WO2012060594A3 WO 2012060594 A3 WO2012060594 A3 WO 2012060594A3 KR 2011008205 W KR2011008205 W KR 2011008205W WO 2012060594 A3 WO2012060594 A3 WO 2012060594A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
thiourea compound
active ingredient
composition containing
Prior art date
Application number
PCT/KR2011/008205
Other languages
English (en)
Korean (ko)
Other versions
WO2012060594A2 (fr
Inventor
전라옥
류재하
천예진
박병현
Original Assignee
숙명여자대학교산학협력단
전북대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 숙명여자대학교산학협력단, 전북대학교산학협력단 filed Critical 숙명여자대학교산학협력단
Publication of WO2012060594A2 publication Critical patent/WO2012060594A2/fr
Publication of WO2012060594A3 publication Critical patent/WO2012060594A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement de maladies inflammatoires, la composition pharmaceutique contenant, en tant que principe actif, un composé thiourée représenté par la Formule 1 suivante ou un sel pharmaceutiquement acceptable de celui-ci. Le composé thiourée ou son sel pharmaceutiquement acceptable, selon la présente invention, réduit l'activité de NF-kB qui provoque des maladies inflammatoires dans un synoviocyte de type fibroblastique et chez un modèle murin d'arthrite induite par le collagène, et inhibe efficacement l'œdème et la douleur. Ainsi, la composition de la présente invention peut être utilisée efficacement dans la prévention et le traitement de maladies inflammatoires, telles que la polyarthrite rhumatoïde.
PCT/KR2011/008205 2010-11-05 2011-10-31 Composition anti-inflammatoire contenant un composé thiourée et un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif WO2012060594A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100109793A KR20120048250A (ko) 2010-11-05 2010-11-05 티오우레아계 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 항염증 조성물
KR10-2010-0109793 2010-11-05

Publications (2)

Publication Number Publication Date
WO2012060594A2 WO2012060594A2 (fr) 2012-05-10
WO2012060594A3 true WO2012060594A3 (fr) 2012-06-28

Family

ID=46024928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008205 WO2012060594A2 (fr) 2010-11-05 2011-10-31 Composition anti-inflammatoire contenant un composé thiourée et un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif

Country Status (2)

Country Link
KR (1) KR20120048250A (fr)
WO (1) WO2012060594A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101639599B1 (ko) * 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
CN111830254B (zh) * 2020-07-29 2022-07-26 武汉生之源生物科技股份有限公司 一种基质金属蛋白酶-3测定试剂盒及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048108A2 (fr) * 2001-11-29 2003-06-12 Theracos, Inc Composes servant au traitement d'une inflammation, des diabetes et des troubles associes
WO2009058739A1 (fr) * 2007-10-29 2009-05-07 Schering Corporation Dérivés d'urée et de thiourée hétérocycliques et leurs procédés d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048108A2 (fr) * 2001-11-29 2003-06-12 Theracos, Inc Composes servant au traitement d'une inflammation, des diabetes et des troubles associes
WO2009058739A1 (fr) * 2007-10-29 2009-05-07 Schering Corporation Dérivés d'urée et de thiourée hétérocycliques et leurs procédés d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHUN, YE JIN ET AL.: "Synthesis of Heterocycle-linked Thioureas and Their Inhibitory Activities of No Production in LPS Activated Macrophages", BULL. KOREAN CHEM. SOC., vol. 31, no. 1, 20 January 2010 (2010-01-20), pages 27 - 30 *
LEE, YR ET AL.: "SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast-like synoviocytes and mice with collagen-induced arthritis", BR. J. PHARMACOL., vol. 164, September 2011 (2011-09-01), pages 794 - 806 *

Also Published As

Publication number Publication date
KR20120048250A (ko) 2012-05-15
WO2012060594A2 (fr) 2012-05-10

Similar Documents

Publication Publication Date Title
WO2010088000A3 (fr) Composés antifibrotiques et leurs utilisations
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
MY161001A (en) Tetrahydrocarboline Derivative
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
WO2012162254A8 (fr) Inhibiteurs de l'activité lrrk2 kinase
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
NZ605469A (en) Nalbuphine-based formulations and uses thereof
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
WO2012050831A3 (fr) Traitement combiné d'affections dermatologiques
SG178975A1 (en) Indenone derivative and pharmaceutical composition comprising same
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2017022962A8 (fr) Composition pour la prévention ou le traitement d'une maladie immunitaire, comprenant un inhibiteur de la rip kinase en tant que principe actif
WO2009109654A8 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1
WO2013022243A3 (fr) Nouveau dérivé biphénylé ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique pour prévenir ou traiter les maladies inflammatoires ou les maladies auto-immunes comprenant ce dérivé ou ce sel comme principe actif
WO2014056824A3 (fr) Composition de soins de bouche
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
JP2011512394A5 (fr)
WO2012060594A3 (fr) Composition anti-inflammatoire contenant un composé thiourée et un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
TN2010000120A1 (en) Galenical formulations of organic compounds
WO2015100348A8 (fr) Réduction des chéloïdes au moyen d'allantoïne topique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11838199

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11838199

Country of ref document: EP

Kind code of ref document: A2